Stockscreener 앱 받기
104.06
0.79%
-0.83
시간 외 거래:
104.02
-0.04
-0.04%
전일 마감가:
$104.89
열려 있는:
$104.15
하루 거래량:
7.88M
Relative Volume:
0.84
시가총액:
$180.06B
수익:
$46.59B
순이익/손실:
$5.41B
주가수익비율:
33.64
EPS:
3.0938
순현금흐름:
$7.38B
1주 성능:
+2.20%
1개월 성능:
+1.41%
6개월 성능:
+7.49%
1년 성능:
-19.04%
1일 변동 폭
$103.54
$104.87
1주일 범위
$101.69
$105.88
52주 변동 폭
$81.97
$132.03
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
104.06 | 180.06B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.77 | 118.67B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
297.94 | 114.28B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.05 | 65.29B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.22 | 50.27B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-07 | 개시 | Barclays | Overweight |
| 2026-10-02 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2026-08-13 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2026-07-01 | 개시 | Robert W. Baird | Outperform |
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
2 Industries Beyond AI With Long-Term Demand Drivers for 2027 - Zacks Investment Research
UBS reiterates Buy on Abbott Labs stock, cites biosimilars pipeline By Investing.com - Investing.com India
3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case. - The Motley Fool
Alert incorrectly tagged to Abbott Laboratories withdrawn - marketscreener.com
Abbott Laboratories expected to post earnings of $1.42 a shareEarnings Preview - TradingView
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q3 Earnings - Benzinga
Abbott Laboratories stock at EUR 93.23 ahead of the Xetra open - ad-hoc-news.de
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. - The Motley Fool
Is Abbott Laboratories (ABT) Undervalued Following Product Launches And Growth Expectations? - Simply Wall Street
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle - The Motley Fool
StoneX reiterates Buy on Abbott Labs stock ahead of earnings By Investing.com - Investing.com India
Abbott Laboratories stock: TD Cowen sets a USD 135.00 target for Abbott Laboratories stock - ad-hoc-news.de
TD Cowen on Abbott Labs (ABT): 'The Stage is Set for a Stronger 2H' - StreetInsider
Reasons to Add STE Stock to Your Portfolio Right Now - Zacks Investment Research
Haemonetics Gains 149.3% in a Year: What's Driving the Rally? - Zacks Investment Research
Is it Apt to Retain Medtronic Stock in Your Portfolio Now? - Zacks Investment Research
Pregnancy Tests Recalled Globally Over False Positives - Gizmodo
Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now? - Zacks Investment Research
Abbott Laboratories To Go Ex-Dividend On October 15th, 2026 With 0.63 USD Dividend Per Share - Moomoo
Abbott Laboratories stock may move 4.7% on earnings release - Investing.com
Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? - Zacks Investment Research
Medtronic Pays More Today. Abbott Raises Its Dividend Faster. Which Stock Wins? - 24/7 Wall St.
SimpleScreen CRC Launch Could Be A Big Moment For Abbott Stock - Simply Wall Street
Should You Add Abbott Stock to Your Portfolio Ahead of Q3 Earnings? - TradingView
Should You Add Abbott Stock to Your Portfolio Ahead of Q3 Earnings? - Yahoo Finance
Want Passive Income for Life? Here Are 2 Dividend Stocks to Buy and Never Sell - The Motley Fool
Abbott (ABT) Gains As Market Dips: What You Should Know - Zacks Investment Research
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Abbott Laboratories (NYSE:ABT): A Quality Stock With Durable Fundamentals - ChartMill
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 - GlobeNewswire Inc.
Abbott Laboratories is More than a Dividend Stock. Here’s Why. - Yahoo Finance
What Is Abbott Laboratories (ABT) Telling Investors With Its New Product Push? - Simply Wall Street
Lake County-based Abbott to pay nearly $385 million over claims it made baby formula in leaky, unsanitary plant - Lake and McHenry County Scanner
Abbott Laboratories (ABT) Debuts Ensure Max Protein Powder With Creatine And HMB - Yahoo Finance
History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio. - The Motley Fool
Abbott (ABT) Stock Could Be 24% Overvalued After Heart Failure News - Yahoo Finance
Abbott Laboratories (ABT), Why Is Fresh Attention Building Around It? - Simply Wall Street
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens - The Motley Fool
Cancer Stocks to Consider as Oncology Innovation Accelerates - Zacks Investment Research
Is it the Right Time to Hold TNDM Stock in Your Portfolio? - Zacks Investment Research
China Adult Feeding Tubes and Formula Market Outlook to 2033Revenue, Volume, Pricing, and Company Share | Forecast Data Reveals Market Entry and Expansion Opportunities - GlobeNewswire Inc.
Is it the Right Time to Add Phibro Stock to Your Portfolio? - Zacks Investment Research
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Is Abbott Laboratories (ABT) a Dividend Bargain After Its 2026 Selloff? - Yahoo Finance
Abbott Laboratories Contamination Lawsuit Ends in $385 Million Settlement — But Nobody's Admitting Anything - https://www.lawnews.co.uk/
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note - Zacks Investment Research
What Will the Libre Duo Launch Mean for Abbott Laboratories (NYSE:ABT)? - Kalkine Media
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
애보트 래버러토리스 주식 (ABT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| John A. McCoy, Jr. | Officer |
Sep 02 '26 |
Proposed Sale |
109.52 |
27 |
2,957 |
0 |
| Robert B. Ford | Officer |
Aug 25 '26 |
Proposed Sale |
115.85 |
398,832 |
46,204,386 |
0 |
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Sale |
115.85 |
398,832 |
46,204,798 |
306,461 |
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Option Exercise |
54.02 |
398,832 |
21,545,946 |
705,293 |
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT |
Aug 11 '26 |
Sale |
109.83 |
5,850 |
642,506 |
70,724 |
| Louis H. Morrone | Officer |
Aug 11 '26 |
Proposed Sale |
109.83 |
5,850 |
642,506 |
0 |
| Robert J. Alpern | Retired Director |
May 15 '26 |
Proposed Sale |
85.25 |
7,587 |
646,791 |
0 |
| Stratton John G | Director |
May 07 '26 |
Buy |
86.82 |
2,000 |
173,640 |
23,319 |
| STARKS DANIEL J | Director |
Apr 27 '26 |
Buy |
92.65 |
10,000 |
926,537 |
6,751,103 |
| Robert J. Alpern | Retired Director |
Apr 27 '26 |
Proposed Sale |
92.55 |
29,211 |
2,703,457 |
0 |
2.09%
1.11%
자본화:
|
볼륨(24시간):